For those who have come in late here is a basic re-cap of why...

For those who have come in late here is a basic re-cap of why CYP are undergoing such a sharp re-valuation. The difficult thing for us small holders is knowing how the market will value CYP once markets in Europe, US and Australia digest this event.

“Extensive trials at Waisman Biomanufacturing in Madison, Wisconsin have now confirmed this state-of-the-art stem cell manufacturing process is capable of producing MSCs for therapeutic application, consistently, efficiently and economically, in a Good Manufacturing Practice (GMP) production environment.”

“a patent-protected process”

“This is a world-first breakthrough that sets Cymerus™ apart”

“critical milestone”

“An equity research report compiled last year by respected biotech analyst Stuart Roberts saliently noted that should Cynata demonstrate an ability to make cells at industrial scale under GMP then it would be in a position to be a “genuine Stem Cell Revolutionary”. “We have just achieved this important goal.”

“We look forward to aggressively pursuing commercial applications for this game changing therapeutic technology.”

“This is a key requirement for pharmaceutical companies as they move to capture the opportunities presented by stem cell medicine.

“The therapeutic use of MSCs is currently being investigated in more than 200 clinical trials around the world in a diverse range of illnesses, including immune disorders, heart disease, stroke, arthritis, fractures, degenerative disc disease, diabetes, lung disorders and eye disease.”

“We cannot overstate how important this process validation is”

http://cynata.com/uploads/default/source/2015/02/89fd7.15.02.19.CynataAchieves.pdf

Cynata executives, who are openly seeking to partner with a large pharmaceutical or biotech major to monetise the Cymerus technology, are talking up a storm, saying they "cannot overstate how important this process validation is" and claiming that "the risk for our shareholders is that we get bought out too cheap".

Cynata’s executive chairman, Stewart Washer, enthuses that stem cell medicine will “change the world,” proving as revolutionary as antibiotics, and that this is "as close to the fountain of youth as you are going to get".

http://www.businessspectator.com.au...cals/australias-next-big-thing-fountain-youth